Search clinical trials for: Resistance to Checkpoint Inhibitors

Total 473394 results

Guangzhou University of Traditional Chinese Medicine
Akeso Pharmaceuticals, Inc.

Recruiting

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Non-small Cell Lung Cancer

China
Fudan University

Recruiting

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Precigen, Inc
National Cancer Institute (NCI)

Recruiting

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical Cancer | HPV-Related Malignancy | HPV-Related Carcinoma

United States
Chuangzhen Chen

Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors (ILDRV1)

Radiotherapy | Immune Checkpoint Blockade | Metastatic Extracranial Malignant Solid Neoplasm | Resistance to Immunotherapy

China
Institut Claudius Regaud
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma (ATPIC)

Melanoma | Immune Defect | Tumor Skin

France
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Metastatic Solid Tumor
National Cancer Centre, Singapore
National University Hospital, Singapore; Singapore General Hospital; Tan Tock... and other collaborators

Recruiting

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (EMPHASIS)

Hepatocellular Carcinoma

Singapore
Haider Mahdi
Merck Sharp & Dohme LLC; ALX Oncology

Recruiting

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Ovarian Cancer

United States
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) (HYPERION)

Esophageal Squamous Cell Carcinoma

China
Pfizer
Eli Lilly and Company; Merck Sharp & Dohme LLC; Merck KGaA, Darmstadt, Germany

Recruiting

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)

Metastatic Colorectal Cancer

United States, Denmark, Spain, Australia, France, Italy, Belgium, Slovakia, Canada, Czechia, Germany, Netherlands, Norway, Poland, Sweden, United Kingdom
Novartis Pharmaceuticals

Recruiting

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

Spain, Italy, Malaysia, China, United States, Greece, Brazil
Shanghai Chest Hospital

Recruiting

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Sanofi

Recruiting

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Cancer | Neoplasm

United States, Israel
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Recruiting

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

Metastatic Colorectal Cancer

United States, Belgium, China, Canada, Denmark, France, Norway, Romania, Spain, United Kingdom, Austria, Brazil, Germany, Netherlands, Argentina, Czechia, Ireland, Italy, Turkey, Chile, Greece, Puerto Rico, Australia, Japan
Gregory Daniels

Recruiting

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Melanoma Stage Iv | Renal Cell Carcinoma, Metastatic

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Celgene; Stand Up To Cancer; Syndax Pharmaceuticals; Rhone-Poulenc... and other collaborators

Completed

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (NA_00084192)

Non-Small Cell Lung Cancer | Epigenetic Therapy

United States
MedImmune LLC

Active, not recruiting

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Advanced Solid Tumors

United States, Spain, Belgium, Italy, Korea, Republic of, Canada, Australia, Hungary, United Kingdom, France, New Zealand
OSE Immunotherapeutics

Terminated

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (ATALANTE-1)

Non Small Cell Lung Cancer

France, Spain, Israel, United States, United Kingdom, Italy, Poland, Czechia, Germany, Hungary
Asan Medical Center
Hoffmann-La Roche

Completed

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab (CLIMB)

Neoplasm Metastasis | Colorectal Neoplasms | Rectal Neoplasms | Colonic Neoplasms

Korea, Republic of
Georgetown University
United States Department of Defense

Suspended

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3

United States
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

In Escalation: All Patients With Solid Tumors and Lymphoma | In Expansion: Melanoma, Non-small Cell Lung Cancer

United States, Italy, Taiwan, Belgium, Spain, Germany, Japan
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Active, not recruiting

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Head and Neck Cancer

United States
University College, London
Hoffmann-La Roche

Active, not recruiting

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)

Non-small Cell Lung Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Advanced Stage Non-small Cell Lung Cancer

United States
University Hospital Heidelberg
Department of Dermatology, Heidelberg University Hospital

Completed

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Sportivumab)

Melanoma | Exercise | PD-1 Antibodies

Germany
Nasser Hanna, M.D.
Bristol-Myers Squibb; Hoosier Cancer Research Network

Terminated

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

United States
University Hospital, Basel, Switzerland

Not yet recruiting

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors (ISCA-CHECK)

Advanced Solid Tumor

Switzerland
Tel Aviv Medical Center

Not yet recruiting

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Triple Negative Breast Cancer
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Zhejiang University

Recruiting

A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients

Immune Checkpoint Inhibitors | Liver Injury

China
Twinpig Biolab, Inc.

Not yet recruiting

Clinical Trial of TB511 in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Prostate Cancer
Assiut University

Not yet recruiting

Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis

Fungal Resistance
Rise Therapeutics LLC

Not yet recruiting

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Melanoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Melanoma Recurrent | Squamous Cell Cancer | Basal Cell Cancer
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CBM588 in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Neoplasm Metastasis
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR

Triple-Negative Breast Cancer
The Methodist Hospital Research Institute

Recruiting

IL-2 Plus Abatacept in FTD

Frontotemporal Degeneration

United States
Xiaojun Chen

Recruiting

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Obesity | Atypical Endometrial Hyperplasia | Progesterone Resistance

China
Genmab
BioNTech SE

Recruiting

Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

Malignant Solid Tumor

Spain
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
University Hospital, Essen
Bristol-Myers Squibb; Advanced Accelerator Applications

Not yet recruiting

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer (NEPI)

Very High Risk Prostate Carcinoma

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Hepatocellular Carcinoma | Radiotherapy | Pembrolizumab | Tumor Thrombosis

China
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
Amsterdam UMC, location VUmc
Maastricht University Medical Center; Erasmus Medical Center; St. Antonius Hospital

Not yet recruiting

Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) (PREOPANC-5)

Borderline Resectable Pancreatic Cancer
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Xiaojun Chen

Recruiting

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Obesity | Atypical Endometrial Hyperplasia | Endometrial Neoplasms | Progesterone Resistance

China
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
H. Lee Moffitt Cancer Center and Research Institute
Angiodynamics, Inc.

Recruiting

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Locally Advanced Pancreatic Cancer

United States

Search clinical trials for: Resistance to Checkpoint Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations